Doctors told her it was “in her head.”Now Olivia Ferro is building a $1B women’s health startup.From misdiagnosis to 80,000+ patients, SheMed is redefining how women access care.Read more about the #ForbesUnder30 Europe Science & Healthcare listers: https://t.co/NyMKv7eVIJ (Photo: Sebastian Nevols for Forbes) ...

Ahead of a general election in October no one seems willing to discuss Brazil’s abortion policies, or the harm they are doing to women in the country https://t.co/vtRRfZIrqDIllustration: Vartika Sharma/Getty Images https://t.co/LzVkpiSNRz ...

Ahead of a general election in October no one seems willing to discuss Brazil’s abortion policies, or the harm they are doing to women in the country https://t.co/qf9Vkv6tok ...

CORPORATE DECK MARCH 26, 2026 DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARÉ BIOSCIENCE, ALL RIGHTS RESERVED Forward-Looking Statements & Disclaimers This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. ("Daré" or the "Company"). This presentation discusses potential future drug and medical device products that are or will be under clinical or preclinical investigation and have not been approved for use ou ...

Core Insights - Daré Bioscience, Inc. is focused on women's health and aims to bridge the gap between scientific advancements and real-world solutions, with significant developments expected in 2026 [2][27]. Business Highlights and Recent Developments - The company launched DARE to PLAY™, a topical sildenafil cream for women, which is the first of its kind with clinical data showing increased genital blood flow within 10 to 15 minutes and improvements in arousal, orgasm, and desire [3][4]. - DARE to RESTORE™ is a new brand of consumer health products aimed at supporting vaginal microbiome balance, with the first product, Flora Sync LF5™, expected to be available in Q2 2026 [4][6]. - DARE to RECLAIM™, a monthly bio-identical hormone therapy product, is targeting the compounded hormone therapy market, estimated at $2.5 to $4.5 billion, with availability expected in early 2027 [7][8]. - Ovaprene®, a non-hormonal contraceptive candidate, is currently in a Phase 3 clinical trial, with completion of enrollment anticipated in 2026 [9][10]. - DARE-HPV, an investigational therapeutic for high-risk HPV infections, is preparing to enter a Phase 2 clinical study with funding from ARPA-H [11][12]. Financial Results and Position - As of December 31, 2025, the company reported approximately $24.7 million in cash and cash equivalents, with working capital of about $3.4 million [16][36]. - In 2025, Daré raised approximately $20.8 million through equity offerings and received significant non-dilutive funding, allowing for the advancement of multiple programs [17][21]. - Operating expenses for 2025 were approximately $14.3 million, a decrease from $23.5 million in 2024, primarily due to lower R&D expenses and stock-based compensation [18][19]. Revenue Outlook - The company expects to begin recording product revenue from DARE to PLAY and Flora Sync LF5 in Q2 2026, with revenue from DARE to RECLAIM targeted for 2027 [23][20].

Are you a permenopausal woman or are you supporting someone who is permenopause? It might be a new word for you. But I am sure that you have met some one of us or maybe you are one of us. You just don't know it yet. Permenopause is the first part and the beginning of the menopause transition leading up to menopause, which is a woman's last bleeding. It lasts for several years and may start in your mid4s, for some earlier, others later. When the ovaries reduce their activity, the hormonal levels drop and can ...

Please welcome Kimberly Batty. It's the holidays. She's in the kitchen with her auntie preparing for guests. The house is full. Family, close friends. Food on the stove, laughter in the air. She moves quickly between the kitchen and the dining table, bringing dishes and making sure everything is just right. There's love all around, joy, togetherness, and yet she feels disengaged. She's home, but not really at home. After everyone leaves, she returns to the kitchen to clean, and suddenly everything shifts. H ...

Core Insights - Hologic's Global Women's Health Index reveals a significant screening gap for preventable health conditions among women, despite some improvements in testing rates for high blood pressure, cancer, and diabetes [1][2][8] Women's Health Screening - In the fifth edition of the Index, 39% of women were tested for high blood pressure, 13% for cancer, and 24% for diabetes, all showing increases from the previous year and reaching five-year highs [2] - STI testing remains stagnant at 10%, unchanged since the first year of the Index, leaving nearly 2 billion women at risk for serious health issues [2][8] Molecular Diagnostics - Hologic's Aptima assays for STIs and HPV are key products, with the BV and CV/TV assays for diagnosing vaginitis becoming the second-largest assay globally [3] - Despite the growth in molecular diagnostics, overall revenues in this segment fell by 3.5% in Q1 of fiscal 2026, attributed to lower sales of certain assays [3] Cervical Health - An estimated 13,490 new cases of invasive cervical cancer are expected in 2026, with around 4,200 deaths, many of which could be prevented through regular screening [4] - Hologic expanded its cervical health portfolio with FDA approval for the Aptima HPV Assay for primary screening [4] Competitive Landscape - QIAGEN received FDA clearance for its QIAstat-Dx Gastrointestinal Panels, enhancing its testing capabilities [5] - GE HealthCare acquired Intelerad, which is expected to generate approximately $270 million in recurring revenues in its first year [6] Stock Performance - Hologic shares have increased by 23.1% over the past 12 months, contrasting with a 6.7% decline in the industry [7] - The company is currently trading at a forward five-year P/E ratio of 16.11X, which is lower than both its median and industry averages [9]

Hello everybody. I don't think there's any moment more defining than how we enter this world. That's the moment of birth. And every day I stand in this intense place where I see every life coming in and I would say that's the quality of birth. Today I want to see and explore how birth quality and civilization is going to change. That one moment which defines the birth quality. I'm not talking about numbers. I'm talking about how healthy a baby comes into this world. I'm talking about how safely a mother goe ...

Core Insights - Daré Bioscience has received a revised Notice of Award from the NIH for approximately $2 million in funding for its investigational product DARE-PTB1, aimed at preventing preterm birth, a condition with no FDA-approved treatment options [1][4] - The funding period has been extended through November 2026, allowing the company to continue its clinical studies [1][4] - DARE-PTB1 is designed to deliver bio-identical progesterone via an intravaginal ring for up to 14 days, targeting at-risk women [2] Funding and Development - The total NIH funding for the DARE-PTB1 project is approximately $2 million, with the latest tranche of about $1 million extended through November 30, 2026 [1][4] - The project began on December 12, 2023, and supports a Phase 1 comparative pharmacokinetics clinical study [4] Company Strategy - Daré Bioscience focuses on addressing unmet needs in women's health through a differentiated pipeline, leveraging non-dilutive grant funding to advance its projects [1][6] - The company aims to provide innovative solutions across various women's health issues, including preterm birth, HPV-related diseases, and sexual health [3][6] Product Insights - DARE-PTB1 benefits from insights gained from the DARE-HRT1 program, which showed positive results in earlier clinical trials using the same IVR technology [3] - The company is also developing other products, such as DARE to PLAY™ Sildenafil Cream, which targets sexual health needs in women [7][8] Market Context - Women's health is often underfunded, and Daré's strategic partnerships, including with the NIH, provide a competitive advantage in advancing its pipeline [6][7] - The company is committed to transforming women's sexual and reproductive health through innovative science and addressing significant gaps in care [17][18]